Xeris Biopharma Holdings, Inc. cotiza a 10.46 USD y tiene una capitalización bursátil de $1.9B. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; …
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | — | $0.01 | $0.06 |
| Estimado | $-0.03 | — | — | $0.05 |
| Sorpresa | — | — | — | +20.0% |
| Métrica | XERS | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 85.4% | 57.0% | +28.4% |
| Operating Margin | 8.5% | -38.6% | +47.1% |
| Net Margin | 0.2% | -33.6% | +33.8% |
| FCF Margin | — | -13.9% | — |
| ROE | 4.0% | -40.4% | +44.4% |
| ROA | 0.1% | -32.0% | +32.1% |
| Current Ratio | 2.19 | 2.84 | -0.65 |
| Debt / Equity | 16.10 | 0.28 | +15.82 |